ArriVent BioPharma, Inc. (AVBP) Cash Flow Statement
Where AVBP’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- −$160.6M
- Capital expenditures
- $0
- Free cash flow
- −$160.6M
- Returned to shareholders
- —
- Change in cash
- −$28.8M cash at year-end $45.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AVBP operating cash flow, capex and free cash flow
AVBP cash flow trends, FY2021–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$12.6MFY2021 | −$160.6MFY2025 | — | |
| Capital expenditures | $0FY2021 | $0FY2025 | — | |
| Free cash flow | −$12.6MFY2021 | −$160.6MFY2025 | — | |
| Stock-based compensation | $66,667FY2021 | $12.5MFY2025 | +270.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AVBP cash flow by activity
AVBP net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AVBP cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$166.3M | −$80.5M | −$69.3M | −$36.9M | −$51.6M |
| Depreciation & amortization | −$3.0M | — | — | $36.9M | — |
| Stock-based compensation | $12.5M | $3.2M | $895,000 | $424,000 | $66,667 |
| Change in working capital | −$3.8M | $7.1M | $12.6M | −$7.1M | −$3.9M |
| Other non-cash items | $0 | $0 | $0 | −$36.9M | $42.9M |
| Cash from operating activities | −$160.6M | −$70.2M | −$55.8M | −$43.6M | −$12.6M |
| Investing activities | |||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | −$71.2M | −$192.5M | $0 | $0 | — |
| Acquisitions & other investing | $0 | $0 | — | — | −$40.0M |
| Cash from investing activities | −$71.2M | −$192.5M | — | — | −$40.0M |
| Financing activities | |||||
| Net borrowing (repayment) | — | — | — | $0 | — |
| Shares issued | $202.6M | $185.9M | $44.9M | $169.7M | $0 |
| Other financing | $432,000 | $631,000 | −$2.1M | $15,000 | $89.9M |
| Cash from financing activities | $203.1M | $186.6M | $42.9M | $169.7M | $89.9M |
| Summary | |||||
| Net change in cash | −$28.8M | −$76.1M | −$13.0M | $126.1M | $37.3M |
| Cash at end of period | $45.5M | $74.3M | $150.4M | $163.4M | $37.3M |
| Free cash flow | −$160.6M | −$70.2M | −$55.8M | −$43.6M | −$12.6M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$49.9M | −$43.3M | −$35.5M | −$35.0M | −$31.4M | −$64.4M | −$20.6M | −$20.6M | −$21.9M | −$17.4M | −$21.2M | −$14.4M |
| Depreciation & amortization | −$515,000 | −$559,000 | −$3.0M | — | — | — | — | — | — | — | — | — |
| Stock-based compensation | $6.7M | $5.5M | $3.2M | $3.7M | $3.3M | $2.3M | $952,000 | $866,000 | $765,000 | $625,000 | $319,000 | $217,000 |
| Change in working capital | $11.6M | −$3.5M | $4.7M | −$4.5M | $2.0M | −$5.9M | $3.5M | $3.4M | $2.0M | −$1.8M | $6.0M | −$1.3M |
| Other non-cash items | −$7.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from operating activities | −$39.6M | −$41.9M | −$30.7M | −$35.8M | −$26.1M | −$68.0M | −$16.2M | −$16.3M | −$19.1M | −$18.6M | −$14.9M | −$15.4M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | $46.1M | $3.6M | −$71.2M | −$50.8M | $13.9M | $36.8M | −$192.5M | $0 | $0 | $0 | $25.0M | $0 |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $0 | — |
| Cash from investing activities | $46.1M | $3.6M | −$71.2M | −$50.8M | $13.9M | $36.8M | −$192.5M | — | — | — | $25.0M | — |
| Financing activities | ||||||||||||
| Shares issued | $85.2M | $54.7M | $34.7M | $86.1M | $75.3M | $6.5M | $0 | $0 | $319,000 | $185.6M | $0 | $0 |
| Other financing | $853,000 | $149,000 | $67,000 | $349,000 | −$227,000 | $243,000 | $55,000 | $531,000 | $44,000 | $1,000 | −$1.1M | −$1.0M |
| Cash from financing activities | $86.1M | $54.9M | $34.7M | $86.5M | $75.1M | $6.8M | $55,000 | $531,000 | $363,000 | $185.6M | −$1.1M | −$1.0M |
| Summary | ||||||||||||
| Net change in cash | $92.6M | $16.6M | −$67.1M | −$93,000 | $62.9M | −$24.4M | −$208.6M | −$15.8M | −$18.7M | $167.0M | $9.0M | −$16.5M |
| Cash at end of period | $154.7M | $62.1M | $45.5M | $112.7M | $112.8M | $49.9M | $74.3M | $282.9M | $298.7M | $317.4M | $150.4M | $141.4M |
| Free cash flow | −$39.6M | −$41.9M | −$30.7M | −$35.8M | −$26.1M | −$68.0M | −$16.2M | −$16.3M | −$19.1M | −$18.6M | −$14.9M | −$15.4M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
AVBP cash generation
In fiscal 2025 (ended September 30, 2025), ArriVent BioPharma generated -$160.6 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$160.6 million. Cash and equivalents fell by $28.8 million over the year.
Related: AVBP income statement, AVBP balance sheet. See the AVBP stock overview for the latest quote and news.
AVBP cash flow FAQ
What is ArriVent BioPharma's free cash flow?
ArriVent BioPharma's free cash flow was -$160.6 million in fiscal 2025: -$160.6 million of operating cash flow minus $0 of capital expenditures It was -$70.2 million a year earlier..
How much cash does ArriVent BioPharma generate from operations?
ArriVent BioPharma generated -$160.6 million of cash from operating activities in fiscal 2025.